G-CSF对心肌梗死合并心力衰竭患者外周血内皮祖细胞和炎性因子的影响

目的 观察应用粒-细胞集落刺激因子(G-CSF)动员内皮祖细胞(EPCs)治疗心肌梗死合并心衰患者合并外周血内皮祖细胞(EPCs)和炎性因子的变化,探讨动员剂G-CSF对外周血及炎性因子的影响.方法 38例心肌梗死合并心衰患者被随机分为G-CSF(600 μg/d,共7 d)组和对照组,12例健康者为空白组.分离、培养EPCs并测定其数量.应用酶联免疫法及放射免疫法检测两组患者及10例健康者血C-反应蛋白(CRP)、白细胞介素-6 (IL-6)、肿瘤坏死因子-α(TNF-α)、基质细胞衍生因子-1(stromal cell-derived factor-1,SDF-1) 的水平.结果 心肌梗死合并心衰患者EPCs数量和血CRP、IL-6、TNF-α及SDF-1水平均明显高于健康者(P<0.05);两组治疗后各组与治疗前相比差异有统计学意义(P<0.05);治疗组CRP水平较对照组明显降低(P<0.01);治疗组血浆SDF-1水平较对照组明显升高 (P<0.01),SDF-1浓度与循环EPCs数量呈正相关;治疗组与对照组相比,IL-6、TNF-α虽有所下降,但差异无统计学意义(P＞0.05).结论 G-CSF可有效动员急性心肌梗死患者外周血EPCs,亦可降低CRP、改变SDF-1的水平.     

支架置入对ACS患者外周血EPCs数量和血清G-CSF浓度的影响

目的:观察支架置入术对急性冠脉综合征(ACS)患者外周血内皮祖细胞(EPCs)数量和血清粒细胞集落刺激因子(G-CSF)浓度的影响及意义。方法:32例行冠状动脉支架置入术的ACS患者根据不同临床类型分为:ST段抬高ACS急诊PCI组(n=7)和非ST段抬高ACS[包括14例非ST抬高心肌梗死(NSTEMI)和11例不稳定心绞痛(UAP)择期PCI组(n=25)],10例同期经冠状动脉造影(CAG)证实无冠状动脉病变者作为对照组(n=10)。分别于术中和术后3 d抽取外周血进行EPCs的分离培养,同时分离血清以备G-CSF浓度检测。于第10 d对EPCs进行鉴定并于倒置相差显微镜下计数内皮祖细胞克隆形成单位(EPC-CFU)以评估外周血EPCs水平。G-CSF浓度检测采用酶联免疫吸附法(ELISA)。结果:①急诊PCI组术前外周血EPC-CFU数量稍高于择期PCI组,但无统计学意义(P>0.05),且均明显少于对照组(P<0.01)。急诊PCI组术前血清G-CSF明显高于择期PCI组,且均明显高于对照组。②急诊PCI组和择期PCI组术后外周血EPCs数量及血清G-CSF均有增高,但后者外周血EPCs数量增加幅度明显大于前者,对照组外周血EPCs数量及血清G-CSF改变无统计学意义(P>0.05)。③择期PCI组外周血EPCs增加数量与血清G-CSF改变相关(r=0.261,P=0.009),急诊组则无。结论:择期PCI患者术后外周血EPCs数量明显增加,且与血清G-CSF改变相关。AMI后急诊PCI患者术后血清G-CSF浓度明显升高但与外周血EPCs数量增加无明显相关。     

急性心梗合并左心衰患者的临床护理

目的:分析急性心梗合并左心衰患者的临床护理方法,总结护理干预效果.方法:选取所在医院2015年2月至2016年10月84例急性心梗合并左心衰患者,随机分组,对照组(n=42)给予常规护理干预,观察组(n=42)给予全面护理干预,对比两组患者临床治疗效果.结果:观察组卧床时间、症状缓解时间、住院时间均低于对照组(P<0.05),但是观察组患者对护理人员各项满意度评分均高于对照组,组间存在显著差异(P<0.05);观察组并发症发生率(7.14%)均低于对照组(28.57%),组间差异明显(P<0.05).结论:全面护理干预临床效果明显,可快速改善患者临床症状,提高患者就诊满意度,值得临床推广.     

替米沙坦对高血压合并冠心病患者心功能及炎性因子的影响

目的探讨替米沙坦对高血压合并冠心病患者心功能及炎性因子的影响。方法将126例高血压合并冠心病患者随机分为对照组与观察组,对照组60例患者给予硝苯地平缓释片降压,观察组66例给予替米沙坦口服,疗程均为6个月,比较治疗前后两组患者血压、心功能及炎性因子的改变。结果治疗后6个月两组收缩压及舒张压均无显著差别(P>0.05);观察组左室射血分数(LVEF)、心脏指数(CI)及心脏舒张功能指标E/A比值显著优于对照组(P<0.05);观察组治疗后血清超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)显著低于对照组(P<0.05)。结论替米沙坦可显著减少高血压合并冠心病患者血清炎症因子水平,改善患者心功能及左室重塑,有利于改善患者预后。     

研究全麻复合硬膜外麻醉对老年患者外周血炎性因子和调节性T细胞的影响

目的分析老年患者采用全麻复合硬膜外麻醉对外周血炎性因子和调节性T细胞的影响。方法选取2014年6月至2018年6月在我院进行上腹部手术的120例老年患者,将其随机分为观察组与对照组,各组60例,观察组采用全麻复合硬膜外麻醉,对照组采用全身麻醉。结果与麻醉前相比两组患者切皮后1h外周血IL-6、IL-1β水平有所升高,且观察组切皮后1 h、术后1 d外周血IL-6、IL-1β均低于对照组(P0.05);与麻醉前比较两组患者切皮后1 h外周血CD_4~+、CD_4~+CD_(25)~+的水平有所降低,且观察组切皮后1h、术后1 d均高于对照组(P0.05)。结论对老年患者采用全麻复合硬膜外麻醉能够让患者外周血炎性因子和调节性T细胞得到改善,值得进一步推广应用。     

尼莫地平对高血压脑出血患者炎性因子和神经功能的影响

目的:观察尼莫地平对高血压脑出血患者炎性因子和神经功能的影响。方法:回顾性分析2016年6月至2017年6月的162例高血压脑出血患者的临床资料,按照治疗方式分为对照组79例和研究组83例。对照组采用氨氯地平,研究组采取尼莫地平,比较两组治疗后炎性因子、神经功能及不良反应发生率。结果:在治疗2个疗程后,研究组炎症反应指标ET-1、IL-1β、hs-CRP、IL-6及AQP-4均显著低于对照组,差异有统计学意义(P<0.05);两组病情严重程度均有所改善,且研究组重度障碍显著低于对照组,差异有统计学意义(P<0.05);轻度障碍和中度障碍略高于对照组,差异无统计学意义(P>0.05)。研究组不良反应发生率为3.61%(3/83),明显低于对照组的10.12%(8/79),差异有统计学意义(P<0.05)。结论:对于高血压脑出血患者,应用尼莫地平能够有效改善血流变学指标、降低炎症反应,促进患者神经功能的修复,是一种可实施性强的治疗方案。     

针刺内关穴对慢性心衰小鼠心功能及炎性因子的影响

目的 研究针刺内关穴对慢性心力衰竭小鼠心功能及炎性因子的影响.方法 动物分为正常组、模型组、针刺组,每组各15只,腹腔注射盐酸异丙肾上腺素注射液制备慢性心力衰竭模型.针刺组每日上午行针刺干预,针刺干预结束后,间隔30 min予以腹腔注射盐酸异丙肾上腺素注射液,连续针刺干预4周.正常组和模型组只予捆绑固定,不进行任何治疗.采用多普勒超声检测心功能;采用酶联免疫吸附法(ELISA)进行测定血清细胞因子IL-1β、IL-10、TNF-α 含量.结果 与模型组比较,针刺组在LVEDD、LVESD呈降低趋势,差异具有统计学意义(P<0.01);与模型组比较,针刺组在LVEF、LVFS呈升高趋势,差异具有统计学意义(P<0.01).与模型组比较,针刺组小鼠血清IL-1β、TNF-α 含量均明显降低,差异具有统计学意义(P<0.01).与模型组比较,针刺组小鼠血清IL-10含量呈升高趋势,差异具有统计学意义(P<0.01).结论 针刺内关穴能够增加慢性心衰小鼠LVEDD和LVESD,从而改善心室重塑;降低LVEF和LVFS,改善心功能;还能提高血清中IL-10含量,抑制炎性因子的表达;降低促炎因子IL-1β、TNF-α 含量,减缓炎性反应进程.     

舒冠方对冠心病PCI术后患者外周血EPCs动员和VEGF水平的影响

目的观察舒冠方对冠心病PCI术后患者外周血EPCs动员和VEGF水平的影响。方法符合入选条件而不具有排除条件并成功实施冠状动脉支架置入术的住院患者共40例,随机分为舒冠方组20例和西药组20例,并随机选取健康志愿者10例作为对照。西药组给予基础西药治疗,舒冠方组在基础西药治疗基础上于术后第2天开始给予舒冠方颗粒剂。于术后第4周抽取空腹外周血,应用ELISA法检测治疗前后VEGF水平,采用密度梯度离心法从外周血获取单个核细胞培养14d后免疫荧光进行EPCs鉴定计数。结果舒冠方组与西药组VEGF均明显高于对照组(P0.05),舒冠方组和西药组与对照组EPCs比较,均明显低于对照组(P0.05),治疗后舒冠方组EPCs和VEGF均高于单纯西药治疗的西药组(P0.05)。结论舒冠方能够动员EPCs参与修复损伤血管内膜,与其能够上调外周血中的VEGF水平有关。     

粒细胞集落刺激因子对瓣膜置换患者肾功能、外周血内皮祖细胞和炎性因子的影响

目的观察接受心肺转流术(cardiopulmonary bypass,CPB)瓣膜置换手术的患者,应用粒细胞集落刺激因子(granulocyte colony stimulating factor,G-CSF)动员后,肾功能、外周血内皮祖细胞(endothelial progenitor cells,EPCs)和炎性因子的变化,探讨动员剂G-CSF对CPB瓣膜置换术后患者肾功能、EPCs及炎性因子的影响。方法将40例患者随机分为治疗组(G-CSF,600μg/d,术前共7d)和对照组(不施加干预),每组20例。患者入院时(T1)、术后第1天(T2)、术后第3天(T3)以及术后第7天(T4)采集外周血,测定肌酐(serum creatinine,SCr)、胱抑素C(cystatine C,CysC),计算肾小球滤过率(glomerularfiltration rate,GFR);分离、培养EPCs、并测定其数量。检测2组患者血C-反应蛋白(C-reactive protein,CRP)、白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子(tumornecrosis factor-α,TNF-α)、基质细胞衍生因子-1(stromal cell-derived factor-1,SDF-1)的水平。结果入院时,2组患者各项指标差异无统计学意义(P>0.05)。术后第1天,2组GFR水平低于术前,其余指标均高于术前(P<0.05);治疗组炎性因子水平较对照组降低(P<0.05),GFR、SDF-1、EPCs数量较对照组升高(P<0.05)。术后第3天,2组患者GFR水平均达到最低谷,其余指标均高于术前(P<0.05);治疗组患者肾功能损害比对照组轻,SDF-1、EPCs数量较对照组明显升高(P<0.01),IL-6、TNF-α差异无统计学意义(P>0.05)。术后第7天,2组患者EPCs数量、SDF-1水平均持续增高,但治疗组比对照组变化更加显著(P<0.01)。SDF-1浓度与循环EPCs数量呈正相关,治疗组CRP比对照组明显降低(P<0.05)。结论 CPB患者术后肾功能在第3天明显降低,第7天逐渐恢复至术前水平。G-CSF可增高SDF-1的水平,有效动员CPB瓣膜置换患者外周血EPCs,亦可降低CRP,对术后肾功能起到保护作用。     

瑞舒伐他汀对急性冠脉综合征合并心律失常患者炎性因子的影响

目的：探讨急性冠状动脉综合征（ACS）合并心律失常患者应用瑞舒伐他汀治疗后炎性因子的变化。方法：90例ACS合并心律失常的住院患者,按照ACS类型分为不稳定性心绞痛组46例（UA组）、非ST段抬高心肌梗死组13例（USTEMI组）和ST段抬高心肌梗死组31例（STEMI组）。每组患者入院当日均在常规治疗的基础上加用瑞舒伐他汀治疗,检测每组患者治疗前及治疗后2周的血清高敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）及白细胞介素-18（IL-18）并进行对比分析。结果：3组患者治疗前血清hs-CRP、TNF—α及IL-18水平存在明显差异（P〈0．01）,在接受瑞舒伐他汀治疗2周后血清hs—CRP、TNF—α及IL—18均明显降低,差异有统计学意义（P〈0．01）,且3组患者治疗后各炎性因子间差异无统计学意义（P〉0．05）。结论：瑞舒伐他汀可明显降低ACS合并心律失常患者血清hs—CRP、TNF—α及IL-18的水平。     

内皮祖细胞对心梗后心衰患者心功能改变的影响

目的研究应用粒细胞集落刺激因子动员内皮祖细胞治疗心肌梗死后心力衰竭患者心功能的改变。方法选取38例心肌梗死后心衰患者,随机分成治疗组和对照组,治疗组在常规治疗(包括药物和介入治疗)基础上给予内皮祖细胞动员剂G-CSF(600μg/d)静脉注射,连续注射7 d。检测两组治疗前、治疗后第7天和第4个月BNP值及外周血内皮祖细胞数量,行心脏超声检测LVSD、EDV、LVEF。结果治疗组的内皮祖细胞数量较对照组增加明显,尤其第7天增加有显著差异(P<0.01)。两组患者血浆BNP值较治疗前均显著下降恢复正常值(P<0.01);两组心功能指标治疗后均有所好转(P<0.05),治疗组较对照组改善明显(P<0.05),尤以治疗组LVEF值第4个月增加明显,差异有显著性(P<0.01)。结论内皮祖细胞治疗心肌梗死后心衰患者,可有效减轻心室重构,改善心功能。     

Influence of granulocyte colony-stimulating factor on cardiac function in patients with acute myocardial infarction and leukopenia after revascularization

Background Granulocyte colony-stimulating factor （G-CSF） seems to improve cardiac function and perfusion when used systemically through mobilization of stem cells into peripheral blood, but results of previous clinical trials remain controversial. This study was designed to investigate safety and efficacy of subcutaneous injection of G-CSF on left ventricular function in patients with impaired left ventricular function after ST-segment elevation myocardial infarction （STEMI）. Methods Thirty-three patients （22 men; age, （68.5±6.1） years） with STEMI and with comorbidity of leukopenia were included after successful primary percutaneous coronary intervention within 12 hours after symptom onset. Patients were randomized into G-CSF group who received G-CSF （10 μg/kg of body weight, daily） for continuous 7 days and control group. Results of blood analyses, echocardiography and angiography were documented as well as possibly occurred adverse events. Results No severe adverse events occurred in both groups. Mean segmental wall thickening in infract segments increased significantly at 6-month follow up compared with baseline in both groups, but the longitudinal variation between two groups had no significant difference （P〉0.05）. The same change could also be found in longitudinal variation of wall motion score index of infarct segments （P 〉0.05）. At 6-month follow-up, left ventricular end-diastolic volume of both groups increased to a greater extent, but there were no significant differences between the two groups when comparing the longitudinal variations （P 〉0.05）. In both groups, left ventricular ejection fraction measured by echocardiography ameliorated significantly at 6-month follow-up （P 〈0.05）, but difference of the longitudinal variation between two groups was not significant （P 〉0.05）. When pay attention to left ventricular ejection fraction measured by angiocardiography, difference of the longitudinal variation between groups was significant （P=0.046）. Early diastolic mitral flow velocity deceleration time changed significantly at 6- month follow-up in both groups （P=-0.05）. Conclusions Mobilization of stem cells by G-CSF after reperfusion of infarct myocardium is safe and seems to offer a pragmatic strategy for recovery of myocardial global function.     

粒细胞集落刺激因子对心肌梗死患者PCI术后心功能及内皮功能的影响

目的:探讨粒细胞集落刺激因子(G-CSF)对心肌梗死患者经皮冠状动脉介入(PCI)术后心功能及内皮功能的影响。方法:收集2012年8月~2016年1月收治的急性心肌梗死患者76例,按照随机平行对照法分为观察组、对照组各38例。对照组接受PCI术治疗,观察组在PCI术后加入G-CSF治疗(5μg/kg,皮下注射,3次/d,持续5d)。治疗后2周,采用彩色多普勒超声仪检测心功能参数,采用放射免疫法检测血清心功能指标,采用酶联免疫吸附法(ELISA)测定血清内皮功能指标。结果:治疗前,两组血清心功能指标及内皮功能指标含量的差异无统计学意义。治疗后2周,观察组心输出量(CO)、每搏量(SV)水平显著高于对照组,左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)水平低于对照组;观察组血清中心脏型脂肪酸结合蛋白(H-FABP)、氨基末端B型利钠肽前体(NT-proBNP)、半乳糖凝集素-3(Galectin-3)含量低于对照组,内皮素-1(ET-1)含量低于对照组,一氧化氮(NO)含量高于对照组。结论:G-CSF可增强心肌梗死患者的PCI术后心功能,同时优化血管内皮功能。     

心肌梗死患者溶栓前后的多项炎性因子的变化规律研究

目的:探讨心肌梗死患者溶栓前后的多项炎性因子及VEGF、sICAM-1、sVCAM-1、MMP的变化规律。方法:选取2009年7月～2012年3月于本院进行溶栓治疗的56例心肌梗死患者为观察组,同时期的56名健康人员为对照组,将观察组溶栓前、溶栓后1、3、5、7d和对照组的血清炎性因子和VEGF、sICAM-1、sVCAM-1、MMP-2、MMP-9水平进行检测及比较。结果:观察组术前血清炎性因子及VEGF、sICAM-1、sVCAM-1、MMP-2、MMP-9均高于对照组,而观察组溶栓前至溶栓后1、3、5、7d呈现升后降的趋势,而CRP于溶栓后3d、其他指标则于溶栓后5d至峰值,差异均有统计学意义(P<0.05)。结论:心肌梗死患者溶栓前后的血清炎性因子及VEGF、sICAM-1、sVCAM-1、MMP呈现先升后降的趋势,可作为监测溶栓效果的有效指标。     

Serum granulocyte colony-stimulating factor in patients with chronic renal failure

目的　探讨粒系集落刺激因子 (G CSF)的调节机制及代谢途径。方法　本文运用酶联免疫吸附试验 (ELISA)检测 61例慢性肾功能衰竭 (CRF) / 血液透析患者血清G CSF水平。结果　CRF患者血清G CSF水平明显升高。CRF非血透患者血清G CSF检出率为 80 65% ,血清G CSF水平为566 4 0± 2 0 7 98ng/L。CRF血透患者G CSF检出率为 93 33% ,血透前和血透后G CSF水平分别为 12 55 36±611 2 5ng/L和 1151 61± 599 4 7ng/L。血透组G CSF水平略高于非血透组 ,但两组无明显差异。血透前与血透后患者G CSF水平无明显差异。进一步分析表明 ,G CSF水平与WBC ,BUN或Scr水平无关 (P >0 0 5)。结论　CRF患者血清G CSF水平升高可能是由于肾功能不全导致G CSF清除减少或 /和G CSF产生增加。     

Combined treatment with erythropoietin and granulocyte colony-stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction

Background Erythropoietin （EPO） and granulocyte colony-stimulating factor （G-CSF） are both potential novel therapeutics for use after myocardial infarction （MI）.However,their underlying mechanisms remain unclear and the efficacy of monotherapy with EPO or G-CSF is also controversial.Therefore,we investigated the effects of combined treatment with EPO and G-CSF on neovascularization and cardiac function in post-infarction rats and explored the potential mechanisms.Methods Four groups of rats were used：control （saline injection after MI,i.h.）,EPO （a single dose of 5 000 IU/kg after MI,i.h.）,G-CSF （a dose of 50 μg· kg-1· d-1 for 5 days after MI,i.h.）,and both EPO and G-CSF （EPO＋G-CSF,using the same regiment as above）.Cardiac function was assessed by echocardiography before and 1 day,7 days,14 days and 21 days after MI.CD34＋/Flk-1＋ cells in the peripheral blood were evaluated by flow cytometry before and 3 days,5 days and 7 days after MI.The infarct area and angiogenesis in the peri-infarct area were analyzed.The mRNA and protein expression of vascular endothelial growth factor （VEGF） and stromal-derived factor-1α （SDF-1α） in the peri-infarct area were detected by real-time quantitative RT-PCR and Western blotting.Results Compared with the control and monotherapy groups,the EPO＋G-CSF group had significantly increased CD34＋/ Flk-1＋ endothelial progenitor calls （EPCs）in the peripheral blood （P ＜0.05）,up-regulated VEGF and SDF-1α levels in the peri-infarct region （P ＜0.05）,enhanced capillary density （P ＜0.05）,reduced infarct size （P ＜0.05） and improved cardiac structure and function （P ＜0.05）.G-CSF alone did not dramatically increase EPCs in the peripheral blood,enhance capillary density in the peri-infarct area or reduce infarct size compared with the control group.Conclusions Combined treatment with EPO and G-CSF increased EPCs mobilization,up-regulated VEGF and SDF-1α levels in the post-infarction microenvironment,subsequently enhanced neovascularization in the peri-infarct region and reduced infarct size.All factors contributed to its beneficial effects on cardiac function in post-infarction rats.     

沙库巴曲缬沙坦钠对急性心肌梗死后慢性心力衰竭患者心功能和血清炎症因子的影响

目的 探讨沙库巴曲缬沙坦钠对急性心肌梗死后慢性心力衰竭患者心功能和血清炎症因子的影响.方法 收集2018年5月至2020年12月广州市中西医结合医院91例急性心肌梗死后慢性心力衰竭患者,根据用药分为两组,其中对照组(n=44)予规范化心力衰竭治疗,观察组(n=47)在对照组基础上加沙库巴曲缬沙坦钠,分别统计患者治疗前和...     

Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial

Context  Experimental studies and early phase clinical trials suggest that transplantation of blood-derived or bone marrow–derived stem cells may improve cardiac regeneration and neovascularization after acute myocardial infarction. Granulocyte colony-stimulating factor (G-CSF) induces mobilization of bone marrow stem cells. Objective  To assess the value of stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction. Design, Setting, and Patients  Randomized, double-blind, placebo-controlled trial of patients diagnosed with ST-segment elevation acute myocardial infarction who had successful reperfusion by percutaneous coronary intervention within 12 hours after onset of symptoms in Germany between February 24, 2004, and February 2, 2005. Interventions  Patients were randomly assigned to receive subcutaneously either a daily dose of 10 µg/kg of G-CSF or placebo for 5 days. Main Outcome Measures  The primary end point was reduction of left ventricular infarct size according to technetium Tc 99m sestamibi scintigraphy performed at baseline and at 4 to 6 months after randomization. Secondary end points included improvement of left ventricular ejection fraction measured by magnetic resonance imaging and the incidence of angiographic restenosis. Results  Of the 114 patients, 56 were assigned to receive treatment with G-CSF and 58 were assigned to receive placebo. Treatment with G-CSF produced a significant mobilization of stem cells. Between baseline and follow-up, left ventricular infarct size according to scintigraphy was reduced by a mean (SD) of 6.2% (9.1%) in the G-CSF group and 4.9% (8.9%) in the placebo group (P = .56) and left ventricular ejection fraction was improved by 0.5% (3.8%) in the G-CSF group and 2.0% (4.9%) in the placebo group (P = .14). Angiographic restenosis occurred in 19 (35.2%) of 54 patients in the G-CSF group and in 17 (30.9%) of 55 patients in the placebo group (P = .79). The most common adverse event among patients assigned to G-CSF was mild to moderate bone pain and muscle discomfort. Conclusion  Stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction and successful mechanical reperfusion has no influence on infarct size, left ventricular function, or coronary restenosis. Clinical Trial Registration  ClinicalTrials.gov Identifier: NCT00126100